Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

Michael O'Riordan

October 25, 2023

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

News Conference News TCT 2021

No Harm From Thrombolytics in SCAD Patients With STEMI

Michael O'Riordan

October 13, 2021

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Caitlin E. Cox

October 15, 2020

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

Presentation TCT 2014

Thoughtful Insights

Presenter: Daniel I. Simon

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Thomas D. Stuckey

September 17, 2014

Presentation TCT 2014

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

Presenter: John A. Bittl, Tullio Palmerini, Salvatore Cassese, MD

September 15, 2014

Advertisement

What’s Going to Be Hot at TCT 2025

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

SCAAR Registry Delves Into Left Main Revascularization Outcomes

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

No Harm From Thrombolytics in SCAD Patients With STEMI

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Thoughtful Insights

Case Presentation

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content